GlassScriptPhysician profile
Cayla Rose Mutter
NPI 1841849650
$4,076.39
in general payments reported to CMS, 2019-2025
21 companies · $2,996 in 2025
The $2,996 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $564 · 2024: $517 · 2025: $2,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760 · Travel and Lodging: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,759.76 |
| Travel and Lodging | $1,316.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,839.57 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Novo Nordisk INC | $439.71 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $277.02 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $239.54 | 2023-2025 | Mounjaro, Zepbound, Humulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.93 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Xeris Pharmaceuticals, INC. | $148.53 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $131.11 | 2023-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $128.98 | 2023-2025 | Korlym |
| Tandem Diabetes Care, INC. | $128.67 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $85.65 | 2024-2025 | Repatha, Repatha, Evenity |
| Insulet Corporation | $82.77 | 2023-2025 | Omnipod |
| Esperion Therapeutics, INC. | $67.43 | 2025 | Nexletol |
| Cequr Corporation | $62.97 | 2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $59.08 | 2023-2024 | |
| Ascendis Pharma Endocrinology INC | $55.85 | 2025 | Yorvipath |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $46.56 | 2025 | Twiist |
| Abbvie INC. | $44.87 | 2023-2025 | |
| Ibsa Pharma INC. | $33.81 | 2024 | Licart, Tirosint |
| Beta Bionics, INC. | $19.93 | 2024 | Ilet Bionic Pancreas |
| Antares Pharma, INC. | $16.73 | 2023 | Xyosted, Tlando, Nocdurna |
| Novartis Pharmaceuticals Corporation | $14.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cayla Mutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.